News & Updates
Filter by Specialty:
Erdafitinib prevails in bladder cancer with select FGFRalt
The oral selective pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib demonstrated a survival advantage over chemotherapy, extending multiple efficacy endpoints in individuals with advanced or metastatic urothelial carcinoma (mUC) with FGFR alterations (FGFRalt) after previous anti-PD-(L)1 treatment, findings from the confirmatory phase III THOR trial have shown.
Erdafitinib prevails in bladder cancer with select FGFRalt
22 Jun 2023
Does extended lymph node sampling increase complications?
Patients undergoing more extensive lymph node sampling during surgery for a suspected malignant paediatric renal tumour do not appear to have a higher likelihood of experiencing clinically significant complications, reveals a study.
Does extended lymph node sampling increase complications?
06 Jun 2023
50-percent decrease in severity a meaningful endpoint in chronic pelvic pain
A clinically meaningful endpoint for future therapeutic trials in urological chronic pelvic pain syndrome is a decrease of 30‒50 percent in pelvic pain severity, suggests a study. Clinically significant differences for urinary symptom severity are more appropriately defined separately for males and females.
50-percent decrease in severity a meaningful endpoint in chronic pelvic pain
05 Jun 2023
CKD patients with intracerebral haemorrhage face poor prognosis
Poor outcomes hound several patients with chronic kidney disease (CKD) who develop intracerebral haemorrhage, reveals a study presented at the recent AAN 2023.